5' -O-Alkyl derivatives of 1-[3-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU) were synthesized by selective alkylation and deprotection of 2' ,3' -bis-Otetrahydropyranyl BV-araU to enhance metabolic stability and evaluated for efficacy as oral prodrugs of BV-araU. For comparison, their acyl congeners, and 3'-0and 2'-0-ethyl BV-araU, were also prepared by direct acylation of BV-araU and by selective protection, alkylation, and deprotection, respectively. The 5' -O-alkyl prodrugs were stable in acidic solutions, whereas the 5' -O-acyl analogues were unstable under the same conditions. When incubated with enterobacteria, the 5' -O-acyl derivatives resulted in the formation of BV-uracil through non-enzymatic hydrolysis of BV-araU, but the 5' -O-alkyl prodrugs did not. 5' -0-Short-chain aliphatic alkyl (not longer than butyl) and generally acyl prodrugs gave higher blood concentrations of BV-araU than the aromatic derivatives. Plasma concentrations of BV-araU were equal or slightly higher than those after equivalent oral doses of BV-araU. 5'-0-Ethyl BV-araU was effective against intracerebral, intraperitoneal, and cutaneous infections with herpes simplex virus type 1 in mice. 5'-0-Short-chain aliphatic alkyl derivatives may prove to be useful oral prodrugs of BV-araU because of increased metabolic stability.
Introduction 1-[3-D-Arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU, sorivudine; 1) has potent antiviral activities against herpes simplex virus type 1 (HSV-1) and varicella-zoster virus (VZV) in cell culture (Machida et a/., 1981; Machida and Sakata, 1984; Machida, 1986) .The antiviral effects of 1 against some experimental model infections with HSV-1 were demonstrated in immunocompetent and immuno-suppressed mice (Ijichi et sl., 1990; Machida and Takezawa, 1990; Machida etal., 1990 Machida etal., , 1992 . It has been shown that 1 has some efficacy against simian varicella virus infection when used in low doses in monkeys (Soike et ei., 1984 (Soike et ei., , 1992 . In clinical trials, oral administration of 1 to immunocompetent and immunocompromised patients with herpes zoster infections was effective in reducing the duration of vesicles, erythema, and pain (Niimura, 1990; Hiraoka et aI., 1991) , and 1 has been approved for the treatment of zoster in Japan. Machida et al. (1985) reported that 1 was well absorbed through gastrointestinal tracts and was metabolically stable in mice. uracil (BV-uracil) was detected as the single major metabolic product of 1, in the plasma of rats, dogs, monkeys, and humans after oral administration of 1 Sakamoto et aI., 1990; Soike et el., 1992; Ogiwara et aI., 1990) , while only a small amount of BV-uracil was formed after intravenous injection of 1 in monkeys (Soike et aI., 1992) . Presumably, 1 is deglycosylated by the action of enterobacteria to BV-uracil (Nishimoto et aI., 1990) , which is devoid of activity against VZV (Ashida et aI., unpublished data). BV-uracil is an unnatural base, and its presence in plasma seems to correlate with toxicity of 1 in animals chronically administered (Yoshifune et aI., 1990) .
To prevent the degradation of 1 by enterobacteria, prodrugs of 1 were sought which are metabolically stable' when given orally. The ethylation or benzylation at the 5'or 3'-0 position of 2'-deoxy-5-(trifluoromethyl)uridine (F s Thd) and 2'-deoxy-5-fluorouridine increases the antitumour effect of the parent compounds against sarcoma 180 in mice (Yamashita et a/., 1989) . Thus, 18 5'-0-alkyl derivatives of 1 were synthesized and evaluated as oral prcdruqs by determining their resistance to degradation by enterobacteria and by measuring the blood concentrations of 1 after oral dosing in mice. The corresponding 5'-0-acyl prodrugs, and the 3'-and 2'-Q-ethyl derivatives, were also synthesized and tested for comparison.
Results

Chemistry
For the regioselective alkylation of 1 at the 5', 3', and 2' positions, synthetic methods for the alkylation of 2' ,3' -0isopropylideneuridine at the 5' position described by Blank and Pfleidever (1970) were modified. 2'-0-Ethyl BV-araU (4) was prepared from E-5-(2-bromovinyl)-1-[3~D-ribofuranosyluracil (11) (De Clercq et aI., 1986) via its Q2-2'-cyclo derivative (12) to protect the 3'and 5 1 -h y d r o x y groups. After converting 12 to its bis-O-THP derivative, base cleavage of the O-cyclo bond gave 3' ,5'-bis-0-THP BV-araU (13). The 2;-hydroxy group of 13 was then alkylated, and acid hydrolysis of the THP groups gave 4 in 17% yields from 13 (Fig. 3) .
The 5'-0-acyl derivatives of BV-araU (5a-o) were synthesized by treating 1 with a small excess of the appropriate acyl chlorides. Using crystallization, 5a-o were isolated from the reaction mixtures, giving 16-66% yields from 1 (Fig. 4) . Table 1 shows the melting points, and mass spectra of the synthesized 5'-0-alkyl and acyl BV-araU prodrugs.
EtD
Compounds 2m and 20 were stable in water and aqueous acidic solutions. In contrast, the corresponding acyl prodrugs, 5m and 50, were unstable, especially in the acidic solutions ( Fig. 5 ).
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Fig. 2. Synthetic route for 3' -G-ethyl BV-araU (3). Conditions:
(1) TIPDSCI2, pyridine; (2) DHP, TsOH H20, CH 2CI 2; (3) TBAF, THF; (4) TBDMSCI, imidazole, DMF; (5) C2Hsl, NaH, THF; (6) 1 N HCI, dioxane.
Biological evaluation
The blood level of 1 in mice, 8 h after oral administration of the 5'-0-short-chain aliphatic alkyl BV-araU prodrugs To synthesize the 5'-0-alkyl prod rugs of BV-araU, 1 was converted to 5'-0-tert-butyldimethylsilyl (fBDMS) BV-araU (6) by treatment with tert-butyldimethylchlorosilane (fBDMSCI) in N,N-dimethylformamide (DMF). By using the tetrahydropyranyl group (fHP) at the 2' and 3' positions 6 was protected. It was then deprotected by tetrabutylammonium fluoride (fBAF) to give 2',3'-bis-0-THP BV-araU (7) . Alkylation of 7 by sodium hydride (NaH) and alkyl halides in anhydrous tetrahydrofuran (fHF) followed by deprotection of the THP group with acidic MeOH, gave 5'-0-alkyl BV-araU (2a-8) in 12-17% yields from 7 ( Fig. 1) .
To prepare 3'-0-ethyl BV-araU (3), the 2'-and 5'hydroxy groups of 1 were protected with TBDMS and THP groups. Then 1 was converted to 3'-5'-0-(1,1 ,3,3,tetraisopropyldisiloxane-1,3-diyl) (fIPDS) BV-araU (8) (Machida et aI., 1993) . The THP group was introduced at the 2' position of 8. After deprotection of the 3'-and 5'-hydroxy groups with TBAF in THF, the 5 '-hydroxy group of 2'-0-THP BV-araU (9) was reprotected with TBDMS to give 2'-0-THP-5 /-O-TBDMS BV-araU (10).The 3'-hydroxy group of 10 was alkylated, and then 2'-THP and 5'-TBDMS were removed using acidic MeOH to give 3 in 28% yields from 10 ( Fig. 2 ).
Several studies have described the ester prodrugs of antiherpesviral nucleosides. Some amino acid esters of acyclovir produced a considerable improvement in urinary recovery after oral administration in rats (Beauchamp et ei; . Famciclovir, a diacetyl ester of 6-deoxy-penciolovir, showed better oral absorption than penciclovir in rats (Vere Hodge et al., 1989) . A great number of 2 '-or 5'-esters and diesters or triesters of 6-methoxypurine arabinoside (ara-M) have been synthesized in an attempt to enhance bioavailability and water solubility Moorman et al., 1992) . As in ether prodrugs, the introduction of lipophilic Discussion the 5' position (2p-r) did not show the slow-liberating effect. A comparison of bioavailabilities of the 5 '-O-alkyl prodrugs with those of the 3'-0-or 2 '-O-alkyl prodrugs, showed that oral dosing of 3 gave a blood concentration of 1 almost equal to that after a dosing of 2m, while a dosing of 4 gave a much lower blood concentration of 1 than did a dosing of 2m. Thus, 5 '-O-short-chain aliphatic alkyl prodrugs of BV-araU showed excellent bioavailability, though they did not surpass the bioavailability of the corresponding acyl prodrugs in mice.
Neither 1, nor BV-uracil, was formed. during a 24-h incubation of any of the 5 '-O-alkyl prodrugs tested wilh enterobacteria cells under conditions in which approximately 95% of BV-araU was deglycosylated to BV-uracil (data not shown). In contrast, 3-15% of the 5 '-O-aromatic acyl derivatives changed to BV-uracil during incubation. As the amount of BV-uracil formed from the 5' -O-aromatic acyl prodrugs was almost equal to that of 1 formed during incubation without bacteria cells, these aromatic acyl derivatives may have been non-enzymatically-hydrolyzed to 1 followed by its deglycosylation by the action of enterobacteria. The amount of 5' -O-aliphatic acyl prodrugs, which decomposed into BV-uracil in the presence of enterobacteria cells (15-44 %), was larger than thatfrom 1 through non-enzymatic hydrolysis (3-6%), suggesting that these derivatives could be hydrolyzed both spontaneously and by the action of bacteria cells.
A marked antiviral efficacy was noted for 2m against both intraperitoneal (i.p.) and intracerebral (Lc.) infections with HSV-1 in mice (Table 3) . Treatment with the prodrug 2m exhibited statistically significant increases in the survival rate of mice against l.c. and i.p, infections at doses of 10.8 and 54mg kg-t, respectively. This compound showed also some efficacy against cutaneous infection with HSV-1 in mice (Table 4 ). The morbidity rate and the mean maximum lesion score decreased significantly in mice treated orally with 2m at a dose of 54mg kg-1 or more. These therapeutic effects were equivalent to thOse observed following oral treatment with 1. (2m-o), was somewhat higher than that in mice when 1 was administered independently ( Table 2 ). The levels 4 and 12h after administration were generally equivalent to those in mice given a single dose of 1. The corresponding 5' -O-acyl BV-araU prodrugs resulted in similar blood concentrations of 1. Oral administration of aliphatic alkyl, longer than butyl, derivatives of 1 (2p-r) resulted in decrease in blood concentration of 1 in mice. The 5 '-0aromatic alkyl BV-araU prodrugs, 2b, 2d, 2k, and 21 gave relatively high plasma concentrations of 1, but the levels were slightly lower than those found after administration of 1 directly, or than those resulting from the administration of the corresponding 5' -esters. The exception was 2b, which gave a higher blood concentration 4h after administration than did 5b. The blood concentration of 1 after administration of most of the 5 '-O-aliphatic alkyl and acyl derivatives was higher than that of the aromatic derivatives. Blood concentrations of 1 noted 12 h after administration of 20 and 5a were higher than those noted after dosing of 1, or other prodrugs, suggesting that these two compounds can be regarded as slow-liberating prodrugs. However, introduction of alkyl groups longer than butyl at secondary aliphatic ether groups into the terminal hydroxy groups of ganciclovir and 6-deoxy-ganciclovir improved pharmacokinetic properties and showed in vivo antiherpesviral potency (Winkelmann et al., 1988; Winkler et aI., 1990) . The purpose of developing these prodrugs was to improve oral absorption and solubility in water or organic solvents. The metabolic stability of the parent compound was not of primary concern, although the 2' and 5' ester prod rugs of ara-M were made to improve bioavailability by protecting the mother compound from the catabolic degradation caused by high levels of adenosine deaminase in the intestinal mucosa.
In contrast, the need to develop prodrugs of 1 for oral use had not been considered, because 1 showed good bioavailability, and was metabolically more stable than its deoxyribonucleoside congener, E-5-(2-bromovinyl)-2'-deoxyuridine (BVDU). It was accepted that 1 is resistant to deglycosilation by liver extract (T. Yamaguchi et aI., unpublished data), and BV-uracil is rarely detected in the blood or urine of mice after oral or intravenous administration (Machida et al., 1985) . However, recent studies have shown that BV-uracil often is detected in the plasma of animals other than mice after oral administration of 1, thereby making the development of metabolically more stable oral prod rugs of 1 more desirable. The goal of the study described here was to search for more metabolically stable prod rugs of 1.
In an attempt to obtain resistance to the degradation of 1 by enterobacteria, alkyl groups were introduced at the 5' position of the arabinose moiety of 1. Among the synthesized ethers, 5'-O-short-chain aliphatic alkyl derivatives, such as 2m, gave high BV-araU plasma concentrations in mice after oral dosing, while aromatic ethers and aliphatic alkyl (longer than butyl) derivatives gave generally lower blood concentrations. The low blood concentrations of 1 after dosing with these compounds may be related to their low absorption from GI tract due to low water-solubility, low susceptibility to enzyme(s) by which prodrugs are converted to BV-araU, or both. The blood concentration of 1 after oral dosing of 5 '-O-aromatic alkyl BV-araU prodrugs was lower than that after adrninistration of 5 '-O-aliphatic alkyl prodrugs. These results contrast with those found by Yamashita et al. (1989) , who reported that either 5 '-0-or 3'-0-ethyl, and either 5'-0or 3'-0-benzyl F 3Thd derivatives enhanced the antitumour activity of the mother compound. Although there was little difference in the blood concentrations of 1 after oral administration in mice between 5 '-aliphatic alkyl derivatives and the corresponding acyl BR-araU congeners, the former were resistant to deglycosylation by entero-bacteria. Furthermore, the 5 '-Q-short-chain aliphatic ethers were stable, even in acidic conditions, while the corresponding acyl BR-araU 
Special compounds
Materials and Experimental procedures
General chemistry
Six-week-old Balb/c mice were infected with 3.3 x 10 6 p.f.u, of HSV-1 KOS(S) strain and then received compounds orally, twice daily for 7 days. a. Significance in the difference from the saline-treated control (x2analysis with Yates' correction). b. Significance in the difference from the saline-treated control (the Mann-Whitney U-test).
added. The mixture was stirred at room temperature for 2 h. The reaction mixture was washed with saturated NaHC0 3 and brine, dried (Na2S04), and evaporated in vacua. The residue was dissolved in THF (100ml) and TBAF (1 Min THF, 25ml, 25mmol) was added. The mixture was stirred at room temperature for 1h. The reaction mixture was evaporated in vacua. The residue was dissolved in AcOEt, and the solution was washed with water, dried "(Na2S04), and evaporated in vacua. The residue was separated on a silica gel column chromatography by eluting with hexane-AcOEt (2:3, v/v) to give 2 (8.82g, 85% from 1) as 
1-[3,5-0-(Tetraisapropyldisilaxane-1,3-diyl)-{3-D-
arabinafuranasylj-E-5-(2-bromavinyl)uracil (8). 1,3-Dichloro-1,1,3,3-tetraisopropyldisiloxane (TIPDSCI2, 4.42 ml, 14 mmol) was added to a solution of 1 (3.49g, 10mmol) in dry pyridine (50mI). The mixture was stirred at room temperature for 2 h. After removal of the solvent under reduced pressure, the residue was dissolved in AcOEt, and the solution was washed with water, dried (Na2S04), and evaporated in vacua. The residue was applied on a column of silica gel and eluted with Hexane-AcOH H 20 (320mg, 1.7mmol) were added, and the mixture was stirred at room temperature for 3 h. Pyridine (1ml) was added to the reaction mixture, and evaporated in vacua. The residue was dissolved in THF (120ml) and TBAF (1Min THF, 9.6ml, 9.6mmol ) was added. The mixture was stirred at room temperature for 1h
General methad far the preparatian af 1- (5-0-alkyl-{3-D-arabina-furanasyl}-E-5-(2-bramavinyl}uracil (3a-r) . A mixture of 2 (517mg, 1.0mmol), NaH (60% in mineral oil, 120mg, 3.0mmol), and THF (5ml) was stirred under argon at room temperature for 10min. Alkyl halide (1.1mmol) was added and the mixture was stirred at room temperature for 19h. The reaction mixture was diluted with AcOEt (30ml) and washed with saturated NH 4CI and brine. The organic phase was dried (Na2S04) and concentrated to dryness in vacua. The residue was dissolved in methanol (MeOH, 10ml) and TsOH H 20 (76.1mg, 0.40mmol) was added. The mixture was stirred at room temperature for 2 h. Methad A (2a-21) . The resulting precipitate was collected by filtration and recrystallized from ethanol (EtOH)to afford the title compound.
Methad B (2m-2r) . The solvent was evaporated in vacua, and the residue was applied on a column of silica gel and eluted with CHCI 3-MeOH (96:4, v/v) to afford the title compound as a solid, which was recrystallized from EtOH. BV-araU (1) Compound
1-(2,3-Bis-0-tetrahydropyranyl-{3-D-arabinafuranasyl)-E-5-
(2-bromavinyl}uracil (7) . A mixture of the 1-13-D-arabinofuranosyl-E-5-(2-bromovinyl)uracil (BV-araU, 1, 6.98g, 20mmol), TBDMSCI (3.32g, 22mmol), imidazole (3.00g, 44mmol), and DMF (30ml) was stirred at room temperature for 90min. After removal of the solvent under reduced pressure, the residue was dissolved in ethyl acetate (AcOEt), and the solution was washed with saturated NaHC0 3 and brine, dried (Na2S04), and evaporated in vacua. The residue was dissolved in CH 2CI2 (70ml), and 3,4-Dihydro-2H-pyran (DHP, 8.0ml, 88mmol) and p-Toluenesulphonic acid monohydrate (TsOH H 20, 1.11 g, 5.8mmol) were
Melting points were measured on a Yamato MP-21 melting point apparatus (yamato, Tokyo, Japan) and are uncorrected. Elemental analyses were carried out using a Yanako MT-5 (Yanoko Bunseki Kogyo, Kyoto, Japan). 'H-NMR spectra were recorded at 400MHz on a JEOL GSX-400 spectrometer (Jeol, Akishima, Japan) using tetramethylsilane as an internal standard. Chemical shifts are presented in parts per million (s, singlet; d, doublet; t, triplet; m, multiplet; br, broad; dd, double doublet). All exchangeable protons were detected by the addition of D 20. UV absorption spectra were recorded on a UV-160A spectrophotometer (Shimadzu, Kyoto, Japan). EI mass spectra (MS) were measured on a JEOL AX-500 spectrometer. TLC was done on Merck Kieselgel F254 pre-coated plates (Merck, Frankfurt, Germany). Merck Kieselgel 60 (70-230 mesh) silica gel was used for column chromatography.
and evaporated in vacuo. The residue was dissolved in AcOEt, and the solution was washed with water, dried (Na2S04), and evaporated in vacuo. The residue was separated on a silica gel column chromatography by eluting with CHCIs-MeOH (98:2, v/v) to give 9 (1.58g, 61%) as a foam: 1H-NMR (DMSO-d a) C; 44.36, H; 4.89, N; 6.47, Found C; 44.60, H; 5.02, N; . TBDMSCI (603mg, 4.0mmol) and imidazole (545mg, 8.0mmol) was added to a solution of 9 (1.58g, 3.6mmol) in DMF (20 ml). The mixture was stirred at room temperature for 1 h. After removal of the solvent under reduced pressure, the residue was dissolved in AcOEt, and the solution was washed with water, dried (Na2S04), and evaporated in vacuo. The residue was applied on a column of silica gel and eluted with Hexane-Acost H; 6.62, N; 5.11, Found C; 48.33, H; 6.53, N; 5 .09.
1-(3-0-ethyl-{3-D-arabinofuranosyl)-E-5-(2-bromovinyl)uracil
(3). A mixture of 10 (328mg, 0.60 mmol), NaH (60% in mineral oil, 72.0mg, 1.8mmol) and THF (12ml) was stirred under argon at room temperature for 10min. Ethyl iodide (112mg, 0.72mmol) was added and the mixture was stirred at room temperature for 19 h. The reaction mixture was diluted with AcOEt (30ml) and washed with saturated NH4CIand brine. The organic phase was dried (Na2S04)and concentrated to dryness in vacuo. The residue was dissolved in dioxane (4ml) and treated with 1 N HCI (t.Ornl, 1.0 mmol). The mixture was stirred at 50°C for 1 h, and neutralized With aqueous NaHCO s. The mixture was diluted with AcOEt. The organic phase was washed with water, dried (Na2S04), and evaporated in vacuo. The residue was applied on a column of silica gel and eluted with CHCls-MeOH C; 41.40, H; 4.54, N; 7.43, Found C; 41.59, H; 4.41, N; 7.38. E-5-(2-bromovinylj-2,2'-anhydro-1-{3-D-arabinofuranosyluracil (12) . A mixture of E-5-(2-bromovinyl)-1-13-D-ribofuranosyluracil (11, 7.54g, 22mmol) ,acetylsalicyloyl chloride (10.7g, 54mmol) and CHsCN (75ml) was heated at 50°C for 30min. The resulting precipitate was collected by filtration, and dried under reduced pressure. The precipitate was dissolved in 0.5M NaOMe/MeOH (49ml) and the mixture was stirred at room temperature for 2 h. After neutralization of the mixture by Diaion PK-216 resin (H+ form), the resin was removed by filtration and the filtrate was concentrated under reduced pressure. 330, 332 (M+). Anal Calcd. for C 11 H 11 N 205Br 0.5 H 20, C; 38.84, H; 3.56, N; 8.24, Found C; 38.62, H; 3.34, N; . A mixture of 12 (150mg, 0.45mmol), DHP (0.41ml, 4.5mmol), TsOH H 2o (8.61mg, 0.045mmol) and CHsCN (10ml) was stirred at room temperature for 2h. The reaction mixture was neutralized with concentrated' NH 40H, and evaporated in vacuo. The residue was dissolved in 0.1 M KOHl EtOH (4.5ml), and the solution was stirred at room temperature for 3 h. The solvent was removed under reduced pressure. The residue was dissolved in AcOEt, and washed with water and brine. The organic phase was dried (Na2S04)and the solvent was removed under reduced pressure. The residue was separated on a silica gel column chromatography by eluting with hexane-AcOEt (1:1, vlv) to give 13 (170mg, 73%) as a foam: 1H-NMR (CDCIs) 8, p.p.m. 1.55-1.87 (12H, m, THP), 3.54-4.82 (12H, m), 6.09--6.30 (1H, rn, H-1'), 6.6(}-6.73 (1H, m, m, rn, m, ; MS (EI) m/z 516,518 (M+); Anal Calcd. for C 21 H 29N20 aBr, C; 48.75, H; 5.65, N; 5.41, Found C; 48.51, H; 5.51, N; . A mixture of 13 (517mg, 1.0mmol), NaH (60% in mineral oil, 120 mq, 3.0 mmol) and THF (5ml) was stirred under argon at room temperature for 10min. Ethyl iodide (172mg, 1.1 mmol) was added and the mixture was stirred at room temperature for 19 h. The reaction mixture was diluted with AcOEt (30ml) and washed with saturated NH 4CI and brine. The organic phase was dried (Na2S04)and concentrated to dryness in vacuo: The residue was dissolved in MeOH, and TsOH H20 (76.1mg, 0.40mmol) added. The mixture was stirred at room temperature for 2 h. The solvent was evaporated in vacuo, and the residue was applied on a column of silica gel and eluted with CHCIs-MeOH (97: General method for the preparation of 1- (5-0-acyl-{3-D-arabinofuranosylj-E-5-(2-bromovinyl)uracil (5a-f, n, i, k-o) . A solution of 1 (524mg, 1.5 mmol) in DMF (10ml) was cooled to -15°C. Acid chloride (1.8mmol) and pyridine (0.29ml, 3.6mmol) was added. The mixture was allowed to warm to room temperature and stirred for 2 h. The reaction mixture was evaporated in vacuo. The residue was triturated with water, and then allowed to stand at 4°C overnight. The precipitate was collected by filtration to give the title compound, which was recrystallized from 50% aqueous EtOH.
Stability test
Solutions of 2m, 20, 5m, and 50 (0.5mM)were prepared in 20% methanol, filtered through a 0.45 J.L membrane filter and incubated at 3rC Aromatic alkyl and acyl prodrugs were not tested due to their low solubility.
Blood concentrations of BV-araU in mice
BV-araU, or its prod rugs, were given orally at a dose of 100 urnol kg-1 to 6-week-old Swiss albino ICR male mice (Jcl:ICR strain) purchased from Clea Japan, Inc. Blood was collected with a heparinized syringe from the heart of each mouse at 4, 8, and 12h after drug administration. The plasma thus obtained was individually centrifuged and filtered through a 0.45 J.L membrane filter. The concentration of BV-araU in each plasma specimen was determined by HPLC using a Hitachi L-6000 System. Ten microlitres of each filtered plasma sample was injected onto an Inertsil ODS-2 column (4.6mm J.D. x 250mm L; GL Sciences Inc.). The samples were then eluted at 1.0ml rnln' with 24.75% acetonitrile in 0.1M acetate buffer, pH 4.0. A UV-detector set at 265nm was used for monitoring the eluate.
Degradation by enterobacteria cells
Solutions of each prod rug (0.2mM) were prepared in 20% or 40% DMSO. One-millilitre aliquots were mixed with 1ml of a 20% enterobacterial (Klebsiella pneumoniae) cell suspension prepared in 10 mMphosphate buffer, pH 7.0. The mixture was incubated at 37°C for 24h, then centrifuged at 13000gfor 5min to spin down the bacterial cells. The supernatant was filtered through a 0.45 J.L membrane filter. Degradation of the test compounds was estimated from the formation of BV-araU and BV-uracil by monitoring the filtered supernatant. The supernatant was monitored using HPLC under the same conditions used for the stability test, except that a Hitachi L-6000 System and an Inertsil ODS-2 column were used.
5'-Alkyl and acyl prodrugs of BV-araU 81
Antiviral activity against experimental HSV-1 infection in mice Therapeutic efficacy against experimental l.c, and l.p. infections of mice with HSV-1 were tested in a manner described previously (Machida and Takezawa, 1990; . Briefly, 4-week-old ICR Swiss albino mice were infected with 1.1 x 10 2 p.f.u. (for l.c, infection) or 2.2 x 10 4 p.f.u.(for l.p. infection) of the HSV-1 WT-51 strain. Drugs were orally administered twice daily for 7 days, beginning 4h after infection. The efficacies were estimated by the ditferences in the survival rate and the mean survival time between drug-treated and control mice. These differences were statistically analysed using x 2 analysis with Yates' correction, and the Mann-Whitney U-test, respectively. The effect on cutaneous infections of shaved mice was evaluated as follows: 6-week-old male Balb/c mice, previously shaved with a razor, were cutaneously infected with 3.3 x 10 6 p.f.u. of HSV-1 KOS(S) strain and received the test drug orally, twice daily for 7 days, beginning one day after the infection. Symptoms were scored each day according to criteria described previously (Machida et al., 1992) . Efficacies were estimated by the differences in the morbidity rate (the number of mice with significant symptoms havlnq a lesion score of 3 or higher, divided by the total number of mice) and mean maximum lesion score. These scores were statistically analyzed by x 2 analysis with Yates' correction, and by the Mann-Whitney U-test, respectively.
